Dermata Reports Further Findings from Four-Week Tome Skincare Study
Dermata Therapeutics highlighted additional participant assessments and before-and-after photographs from a cosmetic study of its Tome Foundational Treatment.
Dermata Therapeutics, Inc. (Nasdaq:DRMA) has reported further findings and participant photographs from a recently completed cosmetic study of Tome Foundational Treatment, its once-weekly skin renewal product. The company said the additional material provides information on changes in skin texture, tone, dark spots, smoothness and overall appearance.
The open-label study involved 31 participants. Each participant applied Tome Foundational Treatment one time per week for four weeks, with investigator assessments conducted at multiple points during the study.
The evaluation covered fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance and overall appearance. Participants also completed their own assessments after receiving four treatments.
After four treatments, 77% of participants said they had noticed improvements in their skin after 4 weeks. Separately, 74% agreed that the treatment felt like a professional skincare treatment, while 74% agreed that applying it was worth the results.
Dermata also reported that 77% of participants noticed less downtime, including redness and peeling, with each weekly treatment.
Photographs were taken at the start of the study and after four treatments at the end of the study. Dermata said the images were collected using the Canfield VISIA-CR system to document changes in skin appearance during the four-week treatment period.
The company presented selected participant images to illustrate changes in appearance, while noting that actual results may vary.
Dermata said the treatment was well tolerated in the study, with no treatment-related adverse events reported.
Tome Foundational Treatment is designed for once-weekly use as an addition to an existing skincare routine. Dermata says the product is intended to renew the appearance of skin and improve its tone and texture over time.
The treatment uses Bioneedle™, which Dermata describes as consisting of 100% freshwater sponge. The company says it wild harvests and minimally processes the material into a fine, purified powder.
Gerry Proehl, Dermata’s Chairman, President and Chief Executive Officer, said the company believes clinical demonstrations of visible product benefits are important to building consumer confidence, establishing credibility and supporting consumer adoption. He also said Dermata had received over 1,000 orders for Tome Foundational Treatment since launch.
Dermata describes Tome Foundational Treatment as its first commercial product. The company said additional innovations are planned to follow; the timing and success of planned launches and potential market acceptance remain subject to risks and uncertainties identified by Dermata.
Dermata Therapeutics develops and commercialises direct-to-consumer and professional skincare solutions. The company says it uses experience in clinical dermatology and its Bioneedle technology in developing products for consumer skincare needs. Dermata is headquartered in San Diego, California, and its shares trade on Nasdaq under the symbol DRMA.
Dermata Therapeutics highlighted additional results and participant photographs from a recently completed cosmetic clinical study evaluating Tome Foundational Treatment. The company said the findings provided further insight into changes in skin texture, tone, dark spots, smoothness and overall appearance.
Dermata Therapeutics announced the additional results on November 17, 2026. Participants used Tome Foundational Treatment once per week for four weeks, with assessments conducted at multiple timepoints during the study.
Dermata Therapeutics’ open-label cosmetic clinical study included 31 participants. Participants were evaluated by an investigator and also completed self-evaluations after four treatments.
After four treatments, 77% of participants reported noticing improvements in their skin after 4 weeks. The study evaluated endpoints including fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance and overall appearance.
After four treatments, 74% of participants agreed that Tome Foundational Treatment felt like a professional skincare treatment, while 74% agreed that applying it was worth the results. Dermata also reported that 77% noticed less downtime, including redness and peeling, with each weekly treatment.
The photographs illustrate selected changes in participants’ skin appearance between baseline and after four treatments at the end of the study. Images were obtained using the Canfield VISIA-CR system, and Dermata stated that actual results may vary.
Dermata Therapeutics said the treatment was well tolerated by participants, with no treatment-related adverse events reported in the study.
Tome Foundational Treatment is designed as a once-weekly skin renewal treatment intended to renew the appearance of the skin and improve its tone and texture over time. The company describes it as an addition to an existing skincare routine.
Bioneedle™ is Dermata Therapeutics’ stated hero ingredient and consists of 100% freshwater sponge. The company says it wild harvests and minimally processes the sponge into a fine, purified powder.
Dermata Therapeutics said it had received over 1,000 orders for Tome Foundational Treatment since launch. The statement was made by Gerry Proehl, the company’s Chairman, President and Chief Executive Officer.
Gerry Proehl said Dermata Therapeutics believes demonstrating visible benefits in a clinical setting is important to building consumer confidence, establishing credibility and driving consumer adoption. He also said the company believes participant assessments paired with before-and-after photography can be used to communicate the products’ benefits to consumers and skincare professionals.
Dermata Therapeutics develops and commercialises direct-to-consumer and professional skincare solutions, using its experience in clinical dermatology and Bioneedle technology. Its shares trade on Nasdaq under the ticker symbol DRMA.
Dermata Therapeutics said Tome Foundational Treatment is its first commercial product and that additional innovations are planned to follow. The company’s forward-looking statements are subject to risks and uncertainties, including the timing and success of planned product launches and potential market acceptance.